Gilead Sciences (GILD) Research & Development (2009 - 2026)
Gilead Sciences (GILD) recorded Research & Development of $1.76 billion in Q2 2026, up 18.3% from $1.49 billion a year earlier and up 28.6% from the prior quarter.
Powered by 
Analysis
Gilead Sciences (GILD) Research & Development (2009 - 2026) Analysis & Trends
On a TTM basis, Gilead Sciences' Research & Development came in at $6.07 billion as of Jun 30, 2026, up 2.7% year-over-year; for FY2025, it came in at $5.8 billion, down 1.8% from FY2024.
- Annual Research & Development has a five-year compound annual growth rate of 3.3% (FY2020 to FY2025).
- Across earlier years, Research & Development came in at $5.91 billion in FY2024 (+3.3%), $5.72 billion in FY2023 (+14.9%), $4.98 billion in FY2022 (+8.2%) and $4.6 billion in FY2021 (-6.6%).
- The Q2 2026 figure is the highest quarterly Research & Development in data going back to Q1 2009.
- On a year-over-year basis, Research & Development rose in three of the last eight quarters, with growth averaging 3.0%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 27.7% in Q2 2023, against a decline of 9.3% in Q1 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $1.37 billion (Q1 2026), $1.58 billion (Q4 2025) and $1.35 billion (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Bristol Myers Squibb | 127.55 Bn | 78.82 Bn | 9.25 Bn | 2.96 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.76 Bn |
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.58 Bn |
| Sep 30, 2025 | 1.35 Bn |
| Jun 30, 2025 | 1.49 Bn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.64 Bn |
| Sep 30, 2024 | 1.40 Bn |
| Jun 30, 2024 | 1.35 Bn |
| Mar 31, 2024 | 1.52 Bn |
| Dec 31, 2023 | 1.41 Bn |
| Sep 30, 2023 | 1.46 Bn |
| Jun 30, 2023 | 1.41 Bn |
| Mar 31, 2023 | 1.45 Bn |
| Dec 31, 2022 | 1.55 Bn |
| Sep 30, 2022 | 1.15 Bn |
| Jun 30, 2022 | 1.10 Bn |
| Mar 31, 2022 | 1.18 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.10 Bn |
API Access
Gilead Sciences Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=GILD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "GILD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=GILD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();